Viewing Study NCT03183492


Ignite Creation Date: 2025-12-24 @ 3:28 PM
Ignite Modification Date: 2026-01-20 @ 6:48 PM
Study NCT ID: NCT03183492
Status: WITHDRAWN
Last Update Posted: 2018-03-02
First Post: 2017-05-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel
Sponsor:
Organization:

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count:
Enrollment Type:
Design Primary Purpose:
Design Masking:
Phases:

Phases

Phase Brief Phase Text View
None PHASE4 View
Observational Models:
Time Perspective List:
Who Masked List: